Merck Gains as Investors Cheer New Phase 3 Oncology Data

2026-10-14

Investivoq PriceTracker

Merck & Co. (MRK) is up 3.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is fresh enthusiasm around Merck’s oncology pipeline after the company highlighted multiple late-stage cancer readouts for ESMO 2026, including pivotal Phase 3 data tied to Keytruda and other assets. The move also appears consistent with continued bullish positioning ahead of Merck’s Oct. 26 oncology investor event and its Oct. 29 third-quarter earnings call.

Details:

Merck said it will present first-time pivotal Phase 3 results for intismeran autogene plus Keytruda in resected stage IIB-IV melanoma, with improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda alone.

The company also flagged Phase 3 data for sacituzumab tirumotecan in advanced or recurrent endometrial cancer, describing it as the first and only Phase 3 trial of a TROP2-directed antibody-drug conjugate to improve both overall survival and progression-free survival in that setting.

Merck scheduled an oncology investor event for Oct. 26 in Madrid to discuss strategy and programs, giving investors a near-term catalyst to focus on after the new ESMO disclosures.

Recent analyst-tracked updates show higher price targets and expectations for strong oncology data, which may have reinforced momentum around the stock.

Sources:

Merck, TipRanks, Merck Investor Relations

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRK Insider Trading Activity

$MRK insiders have traded $MRK stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

Here’s a breakdown of recent trading of $MRK stock by insiders over the last 6 months:

JENNIFER ZACHARY (EVP, General Counsel) sold 80,315 shares for an estimated $10,718,494
DAVID MICHAEL WILLIAMS (EVP,Chief Info&Digital Officer) has made 0 purchases and 3 sales selling 52,847 shares for an estimated $6,805,145.
RICHARD R. DELUCA (EVP&Pres, Merck Animal Heallth) has made 0 purchases and 8 sales selling 51,370 shares for an estimated $6,731,142.
CHIRFI GUINDO (EVP, Access, Policy & Comms) has made 0 purchases and 2 sales selling 25,000 shares for an estimated $3,315,000.
DAVID R. MARALDO (EVP & Pres. MMD) has made 0 purchases and 3 sales selling 18,706 shares for an estimated $2,407,797.

To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

$MRK Hedge Fund Activity

We have seen 1,766 institutional investors add shares of $MRK stock to their portfolio, and 1,620 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 54,365,289 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,985,939,636
JPMORGAN CHASE & CO added 43,886,420 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,639,404,970
CAPITAL INTERNATIONAL INVESTORS added 14,516,428 shares (+1668.1%) to their portfolio in Q2 2026, for an estimated $1,865,360,998
FISHER ASSET MANAGEMENT, LLC added 12,079,979 shares (+45.7%) to their portfolio in Q2 2026, for an estimated $1,552,277,301
NORDEA INVESTMENT MANAGEMENT AB removed 5,024,243 shares (-58.9%) from their portfolio in Q2 2026, for an estimated $645,615,225
CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 4,600,064 shares (+9.2%) to their portfolio in Q2 2026, for an estimated $591,108,224
PRICE T ROWE ASSOCIATES INC /MD/ removed 4,524,046 shares (-19.6%) from their portfolio in Q2 2026, for an estimated $581,339,911

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

$MRK Government Contracts

We have seen $3,643,517 of award payments to $MRK over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ERVEBO PROCUREMENT: $190,468

To track government contracts to publicy traded companies, check out Investivoq's government contracts dashboard. You can access data on government contracts through the Investivoq API government contracts endpoint.

$MRK Congressional Stock Trading

Members of Congress have traded $MRK stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $MRK stock by members of Congress over the last 6 months:

REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 3 times. They made 2 purchases worth up to $100,000 on 08/19 and 1 sale worth up to $15,000 on 09/24.

To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

$MRK Price Targets

Multiple analysts have issued price targets for $MRK recently. We have seen 8 analysts offer price targets for $MRK in the last 6 months, with a median target of $139.5.

Here are some recent targets:

Terence Flynn from Morgan Stanley set a target price of $113.0 on 07/09/2026
Mohit Bansal from Wells Fargo set a target price of $150.0 on 07/08/2026
Trung Huynh from RBC Capital set a target price of $142.0 on 07/08/2026
Carter Gould from Cantor Fitzgerald set a target price of $120.0 on 07/06/2026
Louise Chen from Scotiabank set a target price of $155.0 on 06/30/2026
Tim Anderson from B of A Securities set a target price of $141.0 on 06/30/2026
An analyst from CICC set a target price of $138.0 on 06/24/2026

This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.